ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BYSI BeyondSpring Inc

2.29
0.18 (8.53%)
Apr 23 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 112,151
Bid Price 2.21
Ask Price 2.90
News -
Day High 2.379

Low
0.6534

52 Week Range

High
4.00

Day Low 2.175
Company Name Stock Ticker Symbol Market Type
BeyondSpring Inc BYSI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.18 8.53% 2.29 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.18 2.175 2.379 2.29 2.11
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
503 112,151 $ 2.25 $ 252,551 - 0.6534 - 4.00
Last Trade Time Type Quantity Stock Price Currency
16:00:00 1,018 $ 2.29 USD

BeyondSpring Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
87.18M 38.92M - 1.35M -33.28M -0.86 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

BeyondSpring News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BYSI Message Board. Create One! See More Posts on BYSI Message Board See More Message Board Posts

Historical BYSI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.89372.3791.771.9067,9290.396320.93%
1 Month3.533.751.762.73110,635-1.24-35.13%
3 Months0.96794.000.952.77236,2631.32136.59%
6 Months1.024.000.77772.43135,1171.27124.51%
1 Year1.054.000.65341.9998,8361.24118.10%
3 Years10.0533.000.54213.34671,923-7.76-77.21%
5 Years15.1033.000.54213.31457,609-12.81-84.83%

BeyondSpring Description

BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China.

Your Recent History

Delayed Upgrade Clock